QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDVD) Reverse Split of Common Stock Becomes Effective

Endonovo Therapeutics (OTCQB: ENDVD), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, recently announced that its previously announced 1-for-1,000 reverse split of its common stock became effective as of December 19, 2019. Starting today, December 20, 2019, Endonovo’s common stock will trade on the OTC market under the trading symbol ‘ENDVD’ on a split-adjusted basis for a 20-day period. At the end of the 20 days, the ‘D’ will be removed, and the trading symbol will revert back to ‘ENDV’. “With our sales growth and continued expansion of clients, specifically hospitals, this reverse split is a natural next step in our business plan execution. We look forward to executing on the next chapter of our progress given the attractive growth opportunity as well as the solid foundation of our SofPulse(R) business,” Endonovo Therapeutics CEO Alan Collier stated in the news release.

To view the full press release, visit http://ibn.fm/YLvdC

About Endonovo Therapeutics

Endonovo Therapeutics is a commercial-stage developer of noninvasive, wearable Electroceuticals(R) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions, post-concussion syndrome and multiple sclerosis. The company’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver-disease nonalcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The company’s noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php